Oncology Contact Us

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Results from the phase 3 DESTINY-Breast06 trial demonstrated that T-DXd monotherapy improved PFS over chemotherapy in patients with breast cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

April 1st 2025

DecisionDx-Melanoma Test Accurately Identifies Low-Risk SLN Positivity

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.

Roman Fabbricatore

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Leticia Nogueira, PhD, MPH

March 31st 2025

Developers Terminate Clinical Program for Ociperlimab in Lung Cancer

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

April 3rd 2025

EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

April 2nd 2025

EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast Cancer

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

Related Content

Tim Cortese

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Results from the phase 3 DESTINY-Breast06 trial demonstrated that T-DXd monotherapy improved PFS over chemotherapy in patients with breast cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

April 1st 2025

DecisionDx-Melanoma Test Accurately Identifies Low-Risk SLN Positivity

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Roman Fabbricatore

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.

Leticia Nogueira, PhD, MPH

March 31st 2025

Developers Terminate Clinical Program for Ociperlimab in Lung Cancer

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

April 3rd 2025

EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

April 2nd 2025